Computational assessment of the binding modes of the first VHL-recruiting PROTACs designed for oncogenic KRasG12C

被引:0
|
作者
Franca, Tanos C. C. [1 ,2 ,3 ]
Delaire, Eleonore K. M. [1 ]
Drummond, Michael [4 ]
Ebert, Maximilian C. C. J. C. [5 ]
Ajamian, Al [4 ]
Laplante, Steven R. [6 ]
机构
[1] INRS Ctr Armand Frappier Sante Biotechnol, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada
[2] Mil Inst Engn IME, Lab Mol Modeling Appl Chem & Biol Def LMCBD, Praca Gen Tiburcio 80, BR-22290270 Rio De Janeiro, Brazil
[3] Univ Hradec Kralove, Fac Sci, Dept Chem, Rokitanskeho 62, Hradec Kralove 50003, Czech Republic
[4] Chem Comp Grp, Montreal, PQ H3A 2R7, Canada
[5] Congruence Therapeut, 7171 Rue Frederick Banting 117, St Laurent, PQ H4S 1Z9, Canada
[6] NMX Res & Solut Inc, Laval, PQ H7V 5B7, Canada
关键词
RAS-GTP; INHIBITORS; PROTEINS;
D O I
10.1039/d4nj03612c
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A computational investigation was employed to better understand the engagement mechanism for the formation of ternary complexes involving VHL-recruiting PROTACs designed for oncogenic KRasG12C. Rounds of protein-protein docking followed by conformational searches enabled the prediction of the most likely ternary complexes for each PROTAC, which were further validated through rounds of MD simulations. The methodology was applied to six PROTAC molecules (LC1-LC6) that were previously designed, synthesized, tested in cell assays, and reported in the literature. These control systems included five different linker sizes and were derived from the KRasG12C covalent ligand MRTX849 and the VHL ligand 3. Our results suggest that these compounds are capable of engaging KRasG12C and VHL, forming dynamically stable ternary complexes under a predominant binding mode. It was also observed that KRasG12C and VHL exhibit similar dynamic behaviors for binding the PROTAC versus the individual ligand warheads with no linker. Our findings reinforce the concept that this methodology can serve as a powerful tool for designing structures and prioritizing compounds for further synthesis and biological evaluation.
引用
收藏
页码:1596 / 1606
页数:11
相关论文
共 4 条
  • [1] Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs
    Bond, Michael J.
    Chu, Ling
    Nalawansha, Dhanusha A.
    Li, Ke
    Crews, Craig M.
    ACS CENTRAL SCIENCE, 2020, 6 (08) : 1367 - 1375
  • [2] Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
    Yang, Ning
    Fan, Zhiya
    Sun, Shiyang
    Hu, Xiaotong
    Mao, Yaqiu
    Jia, Changkai
    Cai, Xu
    Xu, Tingting
    Li, Bingkun
    Li, Yi
    Han, Luobing
    Wei, Ting
    Qian, Xiaohong
    Qin, Weijie
    Li, Pengyun
    Zheng, Zhibing
    Li, Song
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 261
  • [3] Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
    Yang, Fang
    Wen, Yalei
    Wang, Chaofan
    Zhou, Yuee
    Zhou, Yang
    Zhang, Zhi-Min
    Liu, Tongzheng
    Lu, Xiaoyun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 230
  • [4] BBO-8520, a first-in-class, direct inhibitor of KRASG12C (ON), locks GTP-bound KRASG12C in the state 1 conformation resulting in rapid and complete blockade of effector binding
    Maciag, Anna E.
    Stice, James
    Wang, Bin
    Sharma, Alok
    Chan, Albert
    Lin, Ken
    Singh, Devansh
    Dyba, Marcin
    Yang, Yue
    Setoodeh, Saman
    Smith, Brian P.
    Rabara, Dana
    Zhang, Zuhui
    Larsen, Erik K.
    Esposito, Dom
    Denson, John Paul
    Ranieri, Michela
    Meynardie, Mary
    Mehdizadeh, Sadaf
    Alexander, Patrick
    Blanco, Maria Abreu
    Turner, David
    Xu, Rui
    Lightstone, Felice C.
    Wong, Kwok Kin
    Simanshu, Dhirendra
    Wang, Keshi
    Stephen, Andrew G.
    Sinkevicius, Kerstin
    Nissley, Dwight V.
    Wallace, Eli
    McCormick, Frank
    Beltran, Pedro J.
    CANCER RESEARCH, 2024, 84 (07)